Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SRPK1 | Q96SB4 | 4/20 | 0.39 |
| ▸ | SRPK2 | P78362 | 3/20 | 0.39 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALPG | P10696 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3217145 | 0.86 | KMT2A (0.45) | MEN1GAAKMT2APTK6GRM5 | |
| SCHEMBL13429313 | 0.86 | GAA (0.53) | MEN1GAAKMT2APTK6MAPT | |
| SCHEMBL3214616 | 0.86 | VCP (0.45) | MEN1GAAKMT2APTK6GRM5 | |
| SCHEMBL13428972 | 0.86 | GAA (0.44) | MEN1GAAKMT2APTK6GRM5 | |
| SCHEMBL13429366 | 0.83 | MEN1 (0.43) | MEN1GAAKMT2APTK6PTK2 | |
| SCHEMBL13429256 | 0.82 | MAOA (0.44) | MEN1GAAKMT2APTK6GRM5 | |
| SCHEMBL3222479 | 0.81 | MEN1 (0.41) | MEN1GAAKMT2AMAPTNPSR1 | |
| SCHEMBL13429362 | 0.80 | CACNA1B (0.41) | MEN1GAAKMT2APTK6GRM5 | |
| SCHEMBL13429262 | 0.79 | F2 (0.46) | MEN1GAAKMT2APTK6LMNA | |
| SCHEMBL3214639 | 0.78 | SMN1; SMN2 (0.49) | MEN1GAAKMT2APTK6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | MEN1 2648/4885GAA 1227/4885KMT2A 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.